GPS Project Evaluation of the Impact of the Reorganization of Work Into a Family Medicine Group on Pharmacotherapy and Support for the Autonomy of Seniors With Major Neurocognitive Disorders
GPS Project - Evaluation of the Impact of the Reorganization of Work Into a Family Medicine Group on Pharmacotherapy and Support for the Autonomy of Seniors With Major Neurocognitive Disorders
1 other identifier
interventional
400
1 country
2
Brief Summary
The model of care tested in the GPS project aims to optimize pharmacotherapy for seniors undergoing cognitive assessment or suffering from major neurocognitive disorder (MCND) at home. The goal is to reduce polymedication, inappropriate medications and the treatment burden of seniors and to maintain their cognitive health, quality of life and autonomy. The intervention will include knowledge exchange sessions with nurses, pharmacists, and doctors in FMGs, and increased collaboration between these professionals and home care services teams. Other goal is to increase the satisfaction of the seniors, their families, and the professionals involved in the GPS project.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2021
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2021
CompletedFirst Posted
Study publicly available on registry
May 17, 2021
CompletedStudy Start
First participant enrolled
September 27, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedAugust 22, 2024
August 1, 2024
3.8 years
May 12, 2021
August 20, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in number of prescribed medications
The total number of prescribed medications and 2) the number of potentially inappropriate medications (PIMs) according to the Beers criteria or according to the OptimaMed criteria for participants with advanced MCND will be measured in both groups, before, during and after the study.
Baseline, 3 months and 6 months after inclusion in the study.
Secondary Outcomes (1)
Change in treatment burden
Baseline and 6 months follow-up
Other Outcomes (3)
Change in number of hospitalizations
12 months prior to the start of the intervention and in the 12 months afterwards
Change in number of emergency room visits
12 months prior to the start of the intervention and in the 12 months afterwards
Change in quality of life
Baseline and 6 months follow-up
Study Arms (2)
Exposed FMGs to GPS intervention
EXPERIMENTALPatients who are followed by FMGs exposed to the GPS intervention. They will receive the GPS intervention.
Non exposed FMGs to GPS intervention
NO INTERVENTIONPatients who are part of the FMGs not exposed to the GPS intervention. They will receive the usual care and services.
Interventions
Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
Eligibility Criteria
You may qualify if:
- All seniors (65 years of age or older) undergoing cognitive evaluation OR referred to a memory clinic OR having been diagnosed with cognitive impairment within the last year OR with MCND and followed up at home AND,
- referred to the pharmacist, for the FMGs exposed
- taking prescription medications
You may not qualify if:
- Seniors in palliative care OR
- unable to answer questionnaires in French AND without a caregiver.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CHU de Quebec-Universite Lavallead
- CISSS de Chaudière-Appalachescollaborator
- Ciusss de L'Est de l'Île de Montréalcollaborator
- Fonds de la Recherche en Santé du Québeccollaborator
Study Sites (2)
GMF Bordeaux-Cartierville
Montreal, Quebec, H3M 2X6, Canada
GMF Abénakis
Saint-Georges, Quebec, G5Y 5L6, Canada
Related Publications (1)
Guenette L, Kroger E, Bonnan D, Maheu A, Morin M, Belanger L, Vedel I, Wilchesky M, Sirois C, Durand E, Couturier Y, Sourial N, Dallaire C. Reorganizing Pharmaceutical Care in Family Medicine Groups for Older Adults With or at Risk of Major Neurocognitive Disorders: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2022 Nov 17;11(11):e42577. doi: 10.2196/42577.
PMID: 36264995DERIVED
Study Officials
- STUDY DIRECTOR
Line Guénette, Ph.D
CHU de Québec-Université Laval, Laval University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 12, 2021
First Posted
May 17, 2021
Study Start
September 27, 2021
Primary Completion
July 1, 2025
Study Completion (Estimated)
December 1, 2026
Last Updated
August 22, 2024
Record last verified: 2024-08